In the BioHarmony Drug Report Database

"Preview" Icon

Carfilzomib

Kyprolis (carfilzomib) is a protein pharmaceutical. Carfilzomib was first approved as Kyprolis on 2012-07-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. Kyprolis’s patents are valid until 2033-02-27 (FDA).

 

Trade Name

 

Kyprolis
 

Common Name

 

carfilzomib
 

ChEMBL ID

 

CHEMBL451887
 

Indication

 

multiple myeloma
 

Drug Class

 

Proteozome inhibitors

Image (chem structure or protein)

Carfilzomib structure rendering